Enfamil Breast Milk Composition Claims Should Be Modified - NARB
This article was originally published in The Tan Sheet
Executive Summary
Mead Johnson Advanced Formula Enfamil with Iron breast milk composition claims should be discontinued unless specific conditions are met, the National Advertising Review Board recommends, upholding an earlier National Advertising Division decision.
You may also be interested in...
Nestle Carnation Ad Claims "Denigrating" To Other Infant Formulas - NAD
Nestle USA should cease referring to competing infant formulas as "starter" formulas in its advertising for Carnation Follow-Up, the National Advertising Division of the Council of Better Business Bureaus rules in its May NAD Case Reports.
Similac claim
Appeals court ruling allowing Abbott Labs to use the "1st Choice of Doctors" claim on infant formula "violates the intent of the Lanham Act by rendering evidence of consumer perception legally irrelevant," Mead Johnson tells the U.S. Supreme Court. The Bristol-Myers Squibb division, which markets Enfamil formula, seeks reversal of a Chicago federal appeals court decision finding the claim is not misleading (1"The Tan Sheet" Jan. 17, p. 4). In an opposition brief to the high court, Abbott asserts the appeals court properly ruled "consumer research may not be used to determine the level of substantiation...that an advertiser should possess in order to render its advertising truthful"
Mead Johnson Appealing NAD Enfamil Performance Claim Decision To NARB
Mead Johnson Advanced Formula Enfamil With Iron nutrient content, value and origin ad claims are supported with a few minor stipulations, the National Advertising Division of the Council of Better Business Bureaus concludes in the February NAD Case Reports.